Article by Angela Stelmakowich, Growth Op
A U.S. study exploring the impact of pre- and post cannabis use on liver transplant (LT) outcomes found that there weren’t any.
Published this month in Clinical Transplantation, researchers from the University of California, Los Angeles (UCLA) acknowledge there are some differences.
Although significant differences existed between cannabis users and non-users with respect to recipient demographics, such as the indication for LT and the rate of pre-LT ICU admission, “there were no statistical differences in post-operative outcomes, including patient/graft survival and post-LT complications in pre- or post-LT users,” notes the study abstract.
The experience for cannabis users who underwent surgery for a broken shin bone was far different. Those who consumed cannabis required an average of 37.4 millilitres of anaesthetic compared to 25 mL for non-users, reported pain scores averaging six compared to 4.8 and received 58 per cent more opioids daily while in the hospital. Researchers in the liver transplant study suggest the findings “may help guide future policies regarding marijuana use in LT candidates, although confirmation utilizing larger cohorts is warranted.”
The information may also be of use to U.S. states that preclude cannabis users from giving or getting organ donations, according to High Times.
In a blog post, the National Organization for the Reform of Marijuana Laws reports the UCLA study findings are consistent with other earlier research that found weed use “is not contraindicated in patients receiving organ transplants.”